Clinical trial NCT03799003: A Study of ASP1951 in Subjects With Advanced Solid Tumors
Official title: A Phase 1b Study of ASP1951, a GITR Agonistic Antibody, as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
Conditions: Advanced Solid Tumors
Keywords: ASP1951
cervical cancer
Oncology
squamous cell carcinoma of the head and neck (SCCHN)
metastatic castration-resistant prostate cancer (mCRPC)
melanoma
Tumors
pembrolizumab
colorectal cancer
Advanced (unresectable) or metastatic solid tumor malignancies
Advanced solid tumors
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
Collaborators: name: Merck Sharp & Dohme LLC
First posted: 2019-01-10
Enrollment: 119
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951 when administered as a single agent and in combination with pembrolizumab; and determine the recommended phase 2 dose (RP2D) of ASP1951 and/or maximum tolerated dose (MTD) when administered as a single agent and in combination with pembrolizumab. This study will also evaluate the anti-tumor effect of ASP1951 when administered as a single agent and in combination with pembrolizumab.

Detailed description: This is a dose-escalation and expansion study of ASP1951. The study consists of 3 periods for monotherapy and combination therapy: screening, treatment and follow up, followed by an optional Re-treatment period for participants that qualify.

The monotherapy escalation cohorts will evaluate escalating dose levels of ASP1951 in participants with locally advanced (unresectable) or metastatic solid tumor malignancies including but not limited to squamous cell carcinoma of the head and neck (SCCHN), colorectal cancer, metastatic castration-resistant prostate cancer (mCRPC) and cervical cancer.

The combination escalation cohorts will evaluate escalating dose levels of ASP1951 in combination with a fixed dose of pembrolizumab.

For dose expansion, the tumor-specific cohorts will include participants with squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC) (all PD-L1 status), NSCLC PDL1 high, and cervical cancer, as well as participants with any tumor types that respond to study drug treatment during dose escalation.

Participants may reinitiate study drug treatment in the optional Re-treatment period after confirmation that the participant meets all the re-treatment eligibility criteria.

After discontinuation of study drug, all participants will complete an end-of-treatment visit, along with 30-day and 90 day safety follow-up visits from the last dose of study drug.

Eligibility criteria: Inclusion Criteria:

* Subject has locally-advanced (unresectable) or metastatic solid tumor malignancy (no limit to the number of prior treatment regimens) that is confirmed by available pathology records or current biopsy as well as the following:

  * Subject in the escalation cohort has received all standard therapies (unless the therapy is contraindicated or intolerable) felt to provide clinical benefit the subject's specific tumor type. OR
  * Subject in an expansion cohort has received at least 1 standard therapy for the subject's specific tumor type.

\[Taiwan only\]: Subject has locally-advanced (unresectable) or metastatic solid tumor malignancy (no limit to the number of prior treatment regimens) that is confirmed by available pathology records or current biopsy and has received all standard therapies (unless the therapy is contraindicated or intolerable) felt to provide clinical benefit in the opinion of the treating investigator for his/her specific tumor type. Note: Subjects in the combination expansion cohort with tumor types that pembrolizumab is not approved for can only enroll if their standard treatment is ineffective, unsuitable per investigator's judgment or if the subject is unwilling to receive the standard therapy.

* Subject has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
* Subject's last dose of prior antineoplastic therapy, including any immunotherapy, was 21 days or 5-half-lives, whichever is shorter, prior to initiation of study drug administration. A subject with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) mutation-positive NSCLC is allowed to remain on EGFR tyrosine kinase inhibitor (TKI) or ALK inhibitor therapy until 4 days prior to the start of study drug administration.
* Subject has completed any radiotherapy (including stereotactic radiosurgery) at least 2 weeks prior to study drug administration. Subjects must have recovered from all radiation related toxicities, not require corticosteroids and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to noncentral nervous system \[CNS\] disease.
* Subject's AEs (excluding alopecia) from prior therapy have improved to grade 1 or baseline within 2 weeks prior to start of study treatment.
* Subject with metastatic castration-resistant prostate cancer (mCRPC) (positive bone scan and/or soft tissue disease documented by computed tomography \[CT\]/magnetic resonance imaging \[MRI\]) meets both of the following:

  * Subject has serum testosterone ≤ 50 ng/dL at Screening.
  * Subject has had a bilateral orchiectomy or plans to continue androgen deprivation therapy (ADT) for the duration of study treatment.
* Subject has adequate organ function prior to start of study treatment. If a subject has received a recent blood transfusion, the laboratory tests must be obtained ≥ 4 weeks after any blood transfusion. Subjects can be on stable dose of erythropoietin (≥ approximately 3 months).
* A female subject is eligible to participate if she is not pregnant and at least 1 of the following conditions applies:

  * Not a woman of childbearing potential (WOCBP); OR
  * WOCBP who agrees to follow the contraceptive guidance throughout the treatment period and for at least 6 months after the final study drug administration.
* Female subject must agree not to breastfeed starting at Screening and throughout the study treatment, and for 6 months after the final study drug administration.
* Female subject must not donate ova starting at Screening and throughout the study treatment, and for 6 months after the final study drug administration.
* A male subject with female partner(s) of childbearing potential must agree to use contraception during the treatment period and for at least 6 months after the final study drug administration.
* A male subject must not donate sperm during the treatment period and for at least 6 months after the final study drug administration.
* Male subject with a pregnant or breastfeeding partner(s) must agree to remain abstinent or use a condom for the duration of the pregnancy or time partner is breastfeeding throughout the study period and for 6 months after the final study drug administration.
* Subject agrees not to participate in another interventional study while receiving study drug (Subjects who are currently in the follow-up period of an interventional clinical trial are allowed).

Additional Inclusion Criteria for Subjects in the Expansion Cohorts:

* Subject has at least 1 measureable lesion per RECIST 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions. Subjects with mC RPC who do not have measurable lesions must have at least 1 of the following:

  * Progression with 2 or more new bone lesions; or
  * Prostate-specific antigen (PSA) progression (defined as a minimum of 3 rising PSA levels with an interval of ≥ 1 week between each determination) within 6 weeks prior to study drug administration and a PSA value at the screening visit ≥ 2 ng/mL.
* Subject consents to provide available tumor specimen in a tissue block or unstained serial slides obtained within 56 days prior to first dose of study treatment. Note: This does not apply to subjects with mCRPC who do not have measurable disease.
* Subject is an appropriate candidate for tumor biopsy and consents to undergoing a tumor biopsy (core needle biopsy or excision) during the treatment period as indicated in the Schedule of Assessments. Note: This does not apply to subjects with mCRPC who do not have measurable disease.
* Subject meets one of the following:

  * Subject has the tumor type for which a confirmed response was observed in a monotherapy or combination therapy cohort; or
  * Subject has SCCHN and a combination therapy expansion cohort is opened due to achieving the predicted efficacious exposure or
  * High dose RP2D combination therapy expansion cohorts are opened and subject has NSCLC (all PD-L1 status), NSCLC PD-L1 high\*, SCCHN, or cervical cancer; or
  * Low dose RP2D combination therapy expansion cohorts are opened and subject has NSCLC (all PD-L1 status), SCCHN and cervical cancer.

    * NSCLC with PD-L1 high expressing tumor (tumor proportion score ≥ 50%) as determined by 22C3 PD-L1 immunohistochemistry assay at a local/central laboratory during the screening period. Note: Local 22C3 PD-L1 IHC assay results available within 60 days prior study drug administration may be used for evaluating this entry criterion.

Additional Inclusion Criteria for Re-treatment:

* Subject stopped initial treatment with ASP1951 or ASP1951 in combination with pembrolizumab after attaining a confirmed CR, PR or SD.
* Subject experienced an investigator-determined iCPD after stopping their initial treatment with ASP1951 or ASP1951 in combination with pembrolizumab.
* Subject did not receive any prohibited anti-cancer treatment since the last dose of ASP1951 or ASP1951 in combination with pembrolizumab.
* Subject did not experience a toxicity that met treatment discontinuation criteria during the initial treatment with ASP1951 or ASP1951 in combination with pembrolizumab or pembrolizumab alone.

Exclusion Criteria:

* Subject weighs \< 45 kg.
* Subject has received investigational therapy (other than an investigational EGFR TKI in a subject with EGFR activating mutations or ALK inhibitor in a subject with an ALK mutation) within 21 days or 5-half-lives, whichever is shorter, prior to start of study drug.
* Subject requires or has received systemic steroid therapy or any other immunosuppressive therapy within 14 days prior to study drug administration. Subjects using a physiologic replacement dose of hydrocortisone or its equivalent (defined as up to 30 mg per day of hydrocortisone, 2 mg per day of dexamethasone, or up to 10 mg per day of prednisone) are allowed.
* Subject has symptomatic CNS metastases or subject has evidence of unstable CNS metastases even if asymptomatic (e.g., progression on scans). Subjects with previously treated CNS metastases are eligible, if they are clinically stable and have no evidence of CNS progression by imaging for at least 4 weeks prior to start of study treatment and are not requiring immunosuppressive doses of systemic steroids (\> 30 mg per day of hydrocortisone, \> 2 mg per day of dexamethasone, or \> 10 mg per day of prednisone or equivalent) for longer than 2 weeks.
* Subject has leptomeningeal disease as a manifestation of the current malignancy.
* Subject has an active autoimmune disease that has required systemic treatment in the past 2 years. Subjects with type 1 diabetes mellitus, endocrinopathies stably maintained on appropriate replacement therapy, and skin disorders (e.g., vitiligo, psoriasis or alopecia) not requiring systemic treatment are allowed.
* Subject was discontinued from prior immunomodulatory therapy due to a grade ≥ 3 toxicity that was mechanistically related (e.g., immune related) to the agent.
* Subject has known history of serious hypersensitivity reaction (≥ grade 3) to a known ingredient of ASP1951 or pembrolizumab or severe hypersensitivity reaction to treatment with another monoclonal antibody.
* Subject with positive Hepatitis B virus (HBV) antibodies and surface antigen (indicating acute HBV or chronic HBV) or Hepatitis C (\[HCV\]; ribonucleic acid \[RNA\] detected by qualitative or quantitative assay). Hepatitis C RNA testing is not required in subjects with negative Hepatitis C antibody testing. HBV antibodies are not required in subjects with negative HBV surface antigen.
* Subject has received a live vaccine against infectious diseases within 4 weeks prior to initiation of study treatment.
* Subject has a history of drug-induced pneumonitis (interstitial lung disease), a history of (non-infectious) pneumonitis that required steroids, radiation pneumonitis or currently has pneumonitis.
* Subject has an infection requiring systemic therapy within 2 weeks prior to study drug administration.
* Subject has received a prior allogeneic bone marrow or solid organ transplant.
* Subject is expected to require another form of antineoplastic therapy while on study treatment.
* Subject has had a myocardial infarction or unstable angina within 6 months prior to the start of study treatment or currently has an uncontrolled illness including, but not limited to symptomatic congestive heart failure, clinically significant cardiac disease, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
* Subject has received prior treatment with an anti-glucocorticoid-induced tumor necrosis factor receptor (GITR) antibody.
* Subject has had a major surgical procedure and has not completely recovered within 28 days prior to the start of study treatment.
* Subject has any condition which makes the subject unsuitable for study participation.
* Subject has a known history of human immunodeficiency virus (HIV) infection. No HIV testing is required unless mandated by local health authority.
* Subject has known history of coronavirus disease 2019 (COVID-19) positive polymerase chain reaction (PCR) test within 4 weeks prior to start of study treatment.

Additional Exclusion Criterion for Subjects in Expansion Cohorts:

* Subject has a prior malignancy, other than the current malignancy for which the subject is seeking treatment, active (i.e., requiring treatment of intervention) within the previous 2 years except for locally curable malignancies that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the cervix or breast.

Additional Exclusion Criteria for Re-treatment:

* Subjects who have completed 45 weeks in monotherapy or 57 weeks in combination therapy follow-up with disease control are not eligible for re-treatment.
* Subject currently has an ongoing AE related to ASP1951 or ASP1951 in combination with pembrolizumab that meets the criteria for treatment interruption or discontinuation.

Primary outcomes:
measure: Safety and tolerability assessed by Dose Limiting Toxicity (DLT)
timeFrame: Up to 5 years
measure: Safety and tolerability assessed by adverse events (AEs)
timeFrame: Up to 5 years
measure: Safety and tolerability assessed by immune-related AEs (irAEs)
timeFrame: Up to 5 years
measure: Safety and tolerability assessed by infusion-related reactions (IRRs)
timeFrame: Up to 5 years
measure: Safety and tolerability assessed by serious adverse events (SAEs)
timeFrame: Up to 5 years
measure: Number of participants with laboratory value abnormalities and/or adverse events related to treatment
timeFrame: Up to 5 years
measure: Safety and tolerability assessed by 12- lead electrocardiogram (ECG)
timeFrame: Up to 5 years
measure: Number of participants with vital signs abnormalities and/or adverse events related to treatment
timeFrame: Up to 5 years
measure: Number of participants with Physical Exam abnormalities and/or adverse events related to treatment
timeFrame: Up to 5 years
measure: Safety and tolerability assessed by ECOG performance status
timeFrame: Up to 5 years
measure: Pharmacokinetics (PK) of ASP1951 in serum: AUClast
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: AUCinf
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: AUCinf%extrap
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: AUCtau
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: Cmax
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: Ctrough
timeFrame: Up to 48 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: tmax
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: t 1/2
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: tlast
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: CL
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: Vz
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in serum: Vss
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUClast
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUCinf
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUCinf%extrap
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: AUCtau
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Cmax
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Ctrough
timeFrame: Up to 48 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: tmax
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: t 1/2
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: tlast
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: CL
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Vz
timeFrame: Up to 10 weeks
measure: Pharmacokinetics (PK) of ASP1951 in combination with pembrolizumab in serum: Vss
timeFrame: Up to 10 weeks
measure: Recommended Phase 2 Dose (RP2D) of ASP1951
timeFrame: Up to 5 years
measure: RP2D of ASP1951 in combination with pembrolizumab
timeFrame: Up to 5 years
measure: Maximum Tolerated Dose (MTD) of ASP1951
timeFrame: Up to 5 years
measure: MTD of ASP1951 in combination with pembrolizumab
timeFrame: Up to 5 years
Secondary outcomes:
measure: Objective Response Rate (ORR) per Response Evaluation Criteria In Solid Tumors (RECIST) V1.1 and modified RECIST 1.1 for immune-based therapeutics (iRECIST)
timeFrame: Up to 5 years
measure: Duration of Response (DOR) per RECIST V1.1 and iRECIST
timeFrame: Up to 5 years
measure: Persistence of response after discontinuation per RECIST V1.1 and iRECIST
timeFrame: Up to 5 years
measure: Disease Control Rate (DCR) per RECIST V1.1 and iRECIST
timeFrame: Up to 5 years
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Arizona Clinical Research Cent
state: Arizona
city: Sacramento
country: United States
facility: University of California
state: California
city: Gainesville
country: United States
facility: University of Florida, Davis C
state: Florida
city: Atlanta
country: United States
facility: Emory University
state: Georgia
city: Augusta
country: United States
facility: Augusta University
state: Georgia
city: Chicago
country: United States
facility: Northwestern University
state: Illinois
city: Chicago
country: United States
facility: Rush University Medical Center
state: Illinois
city: Iowa City
country: United States
facility: University of Iowa Hospitals
state: Iowa
city: Detroit
country: United States
facility: Henry Ford Health System
state: Michigan
city: Omaha
country: United States
facility: Nebraska Cancer Specialists
state: Nebraska
city: Las Vegas
country: United States
facility: Comprehensive Cancer Nevada
state: Nevada
city: New Brunswick
country: United States
facility: Rutgers Cancer Institute
state: New Jersey
city: New York
country: United States
facility: Icahn school of Medicine at Mount Sinai
state: New York
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
city: Durham
country: United States
facility: Duke University Medical Center
state: North Carolina
city: Charleston
country: United States
facility: Hollings Cancer Center
state: South Carolina
city: San Antonio
country: United States
facility: South Texas Accelerated Research Therapeutics, LLC
state: Texas
city: Salt Lake City
country: United States
facility: Huntsman Cancer Institute
state: Utah
city: Fairfax
country: United States
facility: Virginia Cancer Specialists
state: Virginia
city: Tacoma
country: United States
facility: Multicare Regional Cancer Center Tacoma
state: Washington
city: Montreal
country: Canada
facility: Site CA15002
city: Montreal
country: Canada
facility: Site CA15005
city: Ontario
country: Canada
facility: Site CA15004
city: Chungcheongbukdo
country: Korea, Republic of
facility: Site KR82002
city: Daegu
country: Korea, Republic of
facility: Site KR82005
city: Gyeonggi-do
country: Korea, Republic of
facility: Site KR82001
city: Seoul
country: Korea, Republic of
facility: Site KR82003
city: Seoul
country: Korea, Republic of
facility: Site KR82004
city: Seoul
country: Korea, Republic of
facility: Site KR82006
city: Seoul
country: Korea, Republic of
facility: Site KR82007
city: Taichung
country: Taiwan
facility: Site TW88603
city: Taipei
country: Taiwan
facility: Site TW88604
Study officials:
affiliation: Astellas Pharma Global Development, Inc.
name: Medical Monitor
role: STUDY_DIRECTOR
References: